From the FDA Drug Label
The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medicine can produce bronchospasm. The use of propranolol (a non-selective beta-blocker) with Anoro Ellipta (umeclidinium and vilanterol) is not directly addressed in the label.
- The label mentions the use of a cardioselective beta-receptor blocker in the context of overdosage, but propranolol is not cardioselective.
- There is no information that directly supports the use of propranolol with Anoro Ellipta. 1
From the Research
Taking Anoro Ellipta (umeclidinium and vilanterol) and propranolol together is generally not recommended due to potential drug interactions. These medications have opposing effects on the body that could reduce their effectiveness and potentially cause adverse reactions. Anoro Ellipta contains vilanterol, a long-acting beta-agonist that opens airways in the lungs, while propranolol is a beta-blocker that blocks the same receptors vilanterol activates. This direct pharmacological opposition means propranolol could significantly reduce the bronchodilating effects of Anoro Ellipta, potentially worsening respiratory symptoms in patients with conditions like COPD or asthma.
Some key points to consider:
- The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA) like umeclidinium and vilanterol has been shown to provide significant improvements in lung function and health-related quality of life in patients with COPD 2, 3, 4.
- However, the use of beta-blockers like propranolol can counteract the effects of LABAs, potentially leading to decreased efficacy and increased risk of bronchospasm 5.
- Recent studies have demonstrated the efficacy of umeclidinium/vilanterol in improving lung function, symptoms, and health-related quality of life in patients with COPD, but these studies do not address the specific interaction with propranolol 6, 4, 5.
- Given the potential risks and the availability of alternative treatment options, it is recommended that patients consult their healthcare provider before taking Anoro Ellipta and propranolol together.
In terms of alternative treatment options, cardioselective beta-blockers may be considered if beta-blocker therapy is necessary, as they have less effect on the lungs compared to non-selective beta-blockers like propranolol. Ultimately, the decision to use Anoro Ellipta and propranolol together should be made on a case-by-case basis, taking into account the individual patient's medical history, current condition, and potential risks and benefits.